[Report] World Congestive Heart Failure Market Research, Trends, Analysis TOC

Background
Pathophysiology
Types of Heart Failure
Left Ventricular (LV) Failure
Right Ventricular (RV) Failure
Systolic Dysfunction
Diastolic Dysfunction
High Output Failure
Theories of Congestive Heart Failure
Hemodynamic Response Theory
Neurohormonal Response Theory
Renal Response Theory
Conditions Leading to Congestive Heart Failure
Myocardial Infarction
Hypertension
Cardiomyopathy
Atrial Fibrillation
Other Risk Factors
Diagnosis of Congestive Heart Failure
Classification of Congestive Heart Failure Patients
- Epidemiology
- United States
- Europe
- Japan

Guidelines for Management of Chronic Heart Failure
Strategies to Maintain Quality Patient Care and Con`tain Costs
- Patient Education Programs
- Dedicated Multidisciplinary Congestive Heart Failure Clinics

Figure 1-1: Incidence of Congestive Heart Failure Cases in the Major World Healthcare Markets: 2007 - 2017
Figure 1-2: Prevalence of Congestive Heart Failure Cases in the Major World Healthcare Markets: 2007 - 2017
Table 1-1: Estimated Market Sizes for CHF Pharmaceuticals in the Major World Healthcare Markets: 2007 - 2017 (US$ Billions)
Figure 1-3: Market Potential Trending and Composition for Congestive Heart Failure Therapeutics in the World' s Major Therapy Markets:2007 - 2017
Figure 1-4: Composition of the Markets for Congestive Heart Failure Therapeutics by Product Classification: 2007 - 2017 Table 1-3: Examples of Companies Competitive in Congestive Heart Failure Therapeutics

Table 2-1: International Cardiovascular Disease (CVD) Statistics
Table 2-2: United States CHF Statistics: 2004
Table 2-3: CHF Data Sources
Table 2-4: Common Contributors to Congestive Heart Failure
Figure 2-1: Incidence and Prevalence of Congestive Heart Failure In the World' s Major Healthcare Markets: 2007 - 2017
Figure 2-2: Incidence Rates of Congestive Heart Failure in the Major World Healthcare Markets: 200l - 2017
Figure 2-3: Prevalence Rates of Congestive Heart Failure in the Major World Healthcare Markets: 2007 - 2017
Figure 2-4: Percentage Breakdown of Deaths from Cardiovascular Diseases: 2003
Table 2-5: Incidence and Prevalence of CHF in the United States: 2007 - 2017
Figure 2-5: Incidence and Prevalence of CHF in the United States: 2007 - 2017
Figure 2-6: The Distribution of Congestive Heart Failure In the Five Major European Healthcare Markets: 2007
Table 2-6: Incidence and Prevalence of CHF in the Major Healthcare Markets of Europe: 2007 - 2017 (Thousands) Figure 2-7: Incidence and Prevalence of CHF in the Major Healthcare Markets of Europe: 2007 - 20017 (Thousands)
Table 2-7: Incidence and Prevalence of CHF in Japan: 2007 - 2017
Figure 2-8: Incidence and Prevalence of CHF in Japan: 2007 - 20017

Table 3-1: Therapeutic Strategies for Symptomatic Congestive Heart Failure
Table 3-2: Pharmacological Response to the Pathophysiology of Cardiac Performance
Table 3-3: Common ACE Inhibitors Recommended for the Treatment of CHF
Table 3-4: Common Angiotensin II Receptor Antagonists Recommended for the Treatment of CHF
Table 3-5: Common Receptor Antagonists Recommended for the Treatment of CHF
Table 3-6: Common Diuretics Recommended for the Treatment of CHF
Table 3-7: Common Inotropic Drugs Available for the Treatment of CHF
Table 3-8: Common Vasodilators Available for the Treatment of CHF
Table 3-9: Common Aldosterone Blocking Drugs Recommended for the Treatment of CHF
Table 3-10: New Drugs in Development for the Treatment of CHF

Figure 4-1: ACC/AHA Guideline Summary for Recommended Therapy of Congestive Heart Failure by Stage of the Disease
Table 4-1: ACC/AHA Staging of Congestive Heart Failure
Table 4-2: 2005 ACC/AHA Guidelines for Evaluation and Therapy for Congestive Heart Failure

Table 5-1: Estimated Market Potential for CHF Pharmaceuticals in the Major World Healthcare Markets: 2007 - 2017
Figure 5-1: Trending in the Estimated Market Potential for CHF Pharmaceuticals in the Major World Healthcare Markets: 2007 - 2017
Figure 5-2: Distribution of the Estimated Market Potential for CHF Pharmaceuticals in the Major World Healthcare Markets: 2007 - 2017
Table 5-2: Estimated Market Potential for CHF Pharmaceuticals in the United States: 2007 - 2017 ($Billions)
Figure 5-3: Trending in the Estimated Market Potential for CHF Pharmaceuticals in the United States: 2007 - 2017
Figure 5-4: Distribution of the Estimated Market Potential by Segments for CHF Pharmaceuticals in the United States: 2007 - 2017
Table 5-3: Estimated Market Potential for CHF Pharmaceuticals in the Major European Markets: 2007 - 2017
Figure 5-5: Trending in the Estimated Market Potential for CHF Pharmaceuticals in the Major European Markets: 2007 - 2017
Figure 5-6: Distribution of the Estimated Market Potential by Segments for CHF Pharmaceuticals in the Major European Markets: 2007 - 2017
Table 5-4: Estimated Market Potential for CHF Pharmaceuticals in the Japanese Market: 2007 - 2017
Figure 5-7: Trending in the Estimated Market Potential for CHF Pharmaceuticals in the Japanese Market: 2007 - 2017
Figure 5-8: Distribution of the Estimated Market Potential by Segments for CHF Pharmaceuticals in the Japanese Market: 2007 - 2017

Congestive Heart Failure: Major World Markets, Volume I: Pharmaceutical Management